CHMMF (Chimeric Therapeutics) Total Liabilities: $5.95 Mil (As of Dec. 2025)


CHMMF Chimeric Therapeutics Ltd CHMMF
13 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is Chimeric Therapeutics Total Liabilities?

Chimeric Therapeutics CHMMF -96.67% 13 Total Liabilities is $5.95 Mil as of Dec. 2025. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Chimeric Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 was $5.95 Mil.

Chimeric Therapeutics's quarterly Total Liabilities increased from Dec. 2024 ($8.07 Mil) to Jun. 2025 ($12.76 Mil) but then declined from Jun. 2025 ($12.76 Mil) to Dec. 2025 ($5.95 Mil).

Chimeric Therapeutics's annual Total Liabilities declined from Jun. 2023 ($11.02 Mil) to Jun. 2024 ($10.89 Mil) but then increased from Jun. 2024 ($10.89 Mil) to Jun. 2025 ($12.76 Mil).

Chimeric Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics Total Liabilities Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
8.95 6.56 11.02 10.89 12.76

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.58 10.89 8.07 12.76 5.95
CHMMF
13GF Score
Chimeric Therapeutics Ltd CHMMF
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chimeric Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Chimeric Therapeutics's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.514+(0+3.243
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.001+0)
=12.76

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=14.044-1.286
=12.76

Chimeric Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.906+(0+1.047
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=5.95

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=3.94--2.013
=5.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $5.95 Mil mean?
Chimeric Therapeutics (CHMMF) has a Total Liabilities of $5.95 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Chimeric Therapeutics and its competitors.
Is Chimeric Therapeutics' Total Liabilities too high?
Chimeric Therapeutics' current Total Liabilities is $5.95 Mil. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' Total Liabilities compare to VRTX and REGN?
Chimeric Therapeutics' Total Liabilities of $5.95 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current Total Liabilities is $5.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current Total Liabilities of $5.95 Mil. The current Total Liabilities is $5.95 Mil. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current Total Liabilities is $5.95 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Other Exchanges CHM:Australia
Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score

Get the complete analysis for CHMMF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price